Treatment of secondary amenorrhea and abnormal uterine bleeding caused by hormonal imbalance in patients without underlying organic pathology such as fibrosis or uterine cancer.

Medroxyprogesterone shares the pharmacologic actions of the progestins. High doses of medroxyprogesterone inhibit pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and will prevent cyclic gonadotropin surges that occur during the normal menstrual cycle.

Pregnancy, malignancy of breast or genital organ, Patients with thrombophlebitis, thromboembolic disorders, cerebral apoplexy, undiagnosed vaginal bleeding, missed abortion.

X

Probably safe

Changes in menstrual flow, spotting, amenorrhea, changes in cervical erosion and secretions, edema, weight gain or loss, cholestatic jaundice, breast tenderness, gastrointestinal disturbances, galactorrhea, and dermatologic effects.

Treatment of secondary amenorrhea and abnormal uterine bleeding, usual oral dosage is 5-10mg daily for 5-10 days.
Mammary carcinoma, prostate carcinoma, or renal carcinoma: Initial, 400 to 1000 mg IM per week. If improvement occurs within a few weeks or months, doses as low as 400 mg/month may maintain patients who have stable disease